Right to Therapeutic Choice | DarshanTalks

In this episode of DarshanTalks Podcast, the host Darshan Kulkarni Pharm.D, MS, Esq. and Guest Speaker Lewis A. Grossman discuss the Right to Therapeutic Choice. Lewis A. Grossman's recently launched book "Choose Your Medicine: Freedom of Therapeutic Choice in America" on the freedom of medicine in the USA. Lewis Grossman, Author, Counsel at Covington & Burling LLP (https://www.cov.com/) and Professor of Law at American University, Washington College of Law, had spoken about government interference in the 19th century on the healthcare industry. The conversation started off with the expert explaining his newly launched book based on freedom of therapeutic choices in America that is affected in American law and policy. The compelled speech doctrine sets out the principle that the government cannot force an individual or group to support certain expressions, this was discussed with compelled action which initially the host gave an example of how cigarette advertisements portray and mention that cigarettes are injurious to health whilst asking the expert to share his insights over this topic. He explains his constitutional law perspective on this subject that what government can make you do and what it cannot, he also mentioned about commercial speech is not protected as supposed to political speech or artistic speech. The conversation also included an interesting topic of off-labeling drugs and ancient drugs like hydroxychloroquine and ivermectin used to treat Covid-19. Furthermore, if the branded company would have endorsed or used these drugs the implications are discussed in this podcast. Also, the subject of monoclonal antibodies was discussed, monoclonal antibodies are proteins created in a lab. The proteins mimic your immune system and are meant to make COVID-19 disease milder in patients who are already sick. As per the expert, the monoclonal antibodies are disseminated by EUA and not FDA approved, highly expensive. They talked about the history of sciences, pharma history, and much more differentiating with the bio-hacking, monoclonal antibodies, hydroxychloroquine, and ivermectin being in the same spectrum. In the mid-segment, what constitutes to be bad-advertisements and how the FDA now is disseminating about bad-ad to the medical industry. Previous Podcast with Lewis A. Grossman: https://www.youtube.com/watch?v=rTRKF... Connect with Lewis A. Grossman: On LinkedIn: https://www.linkedin.com/in/lewis-a-g... Email: lewisg@wcl.american.edu Lewis A. Grossman book link: https://global.oup.com/academic/produ... https://www.amazon.com/dp/0190612754/... Connect with us: Website: http://www.darshantalks.com Law Firm: http://www.kulkarnilawfirm.com Twitter: https://twitter.com/darshantalks ---- Disclaimers: 1. This discussion is merely an oral discussion and should not be relied upon solely on its own to support any conclusion of law or fact. 2. The discussion does not and should not reflect any individual products status as safe, efficacious, adulterated, or misbranded or meeting or not meeting expectations at a local, state, federal, or international agency or organization. 3. The discussion should not be construed to be complete advice that is right for you and may not necessarily represent a specific product. 4. This discussion is provided for general educational purposes and should not be construed as legal advice, regulatory advice, or medical advice. 5. This does not create an attorney-client relationship. Learn more about your ad choices. Visit megaphone.fm/adchoices